1. Home
  2. CXM vs SNDX Comparison

CXM vs SNDX Comparison

Compare CXM & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

HOLD

Current Price

$6.01

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$21.06

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXM
SNDX
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.8B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
CXM
SNDX
Price
$6.01
$21.06
Analyst Decision
Hold
Strong Buy
Analyst Count
9
13
Target Price
$9.89
$80.23
AVG Volume (30 Days)
2.1M
1.2M
Earning Date
03-11-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
180.38
N/A
EPS
0.42
N/A
Revenue
$839,147,000.00
$111,304,000.00
Revenue This Year
$8.25
$617.40
Revenue Next Year
$3.44
$115.70
P/E Ratio
$14.14
N/A
Revenue Growth
6.48
595.65
52 Week Low
$5.80
$8.58
52 Week High
$9.69
$22.73

Technical Indicators

Market Signals
Indicator
CXM
SNDX
Relative Strength Index (RSI) 25.09 50.38
Support Level $5.80 $20.00
Resistance Level $6.16 $21.89
Average True Range (ATR) 0.22 1.04
MACD -0.06 -0.09
Stochastic Oscillator 15.70 40.07

Price Performance

Historical Comparison
CXM
SNDX

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: